Hyloris Pharmaceuticals S.A.
HYL.BR · BRU
6/30/2025 | 3/31/2025 | 12/31/2024 | 9/30/2024 | |
|---|---|---|---|---|
| Market Cap | €175,015 | €167,358 | €189,932 | €171,346 |
| - Cash | €18,615 | €18,615 | €23,594 | €23,594 |
| + Debt | €1,649 | €1,649 | €1,815 | €1,861 |
| Enterprise Value | €158,049 | €150,392 | €168,153 | €149,613 |
| Revenue | €1,670 | €1,670 | €2,701 | €2,701 |
| % Growth | 0% | -38.2% | 0% | – |
| Gross Profit | €1,606 | €1,606 | €2,642 | €2,642 |
| % Margin | 96.2% | 96.2% | 97.8% | 97.8% |
| EBITDA | -€1,610 | -€1,610 | -€610 | -€610 |
| % Margin | -96.4% | -96.4% | -22.6% | -22.6% |
| Net Income | -€1,778 | -€1,778 | -€1,429 | -€1,429 |
| % Margin | -106.5% | -106.5% | -52.9% | -52.9% |
| EPS Diluted | -0.065 | -0.065 | -0.049 | -0.049 |
| % Growth | 0% | -32.7% | 0% | – |
| Operating Cash Flow | -€1,671 | -€1,671 | -€1,675 | -€1,675 |
| Capital Expenditures | €0 | €0 | -€4 | -€4 |
| Free Cash Flow | -€1,671 | -€1,671 | -€1,679 | -€1,679 |